These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 8400801

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Antisense oligodeoxyribonucleotide down-regulation of bcl-2 gene expression inhibits growth of the low-grade non-Hodgkin's lymphoma cell line WSU-FSCCL.
    Smith MR, Abubakr Y, Mohammad R, Xie T, Hamdan M, al-Katib A.
    Cancer Gene Ther; 1995 Sep; 2(3):207-12. PubMed ID: 8528964
    [Abstract] [Full Text] [Related]

  • 3. A bcl-2/IgH antisense transcript deregulates bcl-2 gene expression in human follicular lymphoma t(14;18) cell lines.
    Capaccioli S, Quattrone A, Schiavone N, Calastretti A, Copreni E, Bevilacqua A, Canti G, Gong L, Morelli S, Nicolin A.
    Oncogene; 1996 Jul 04; 13(1):105-15. PubMed ID: 8700536
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Consequences of the t(14;18) chromosomal translocation in follicular lymphoma: deregulated expression of a chimeric and mutated BCL-2 gene.
    Hua C, Zorn S, Jensen JP, Coupland RW, Ko HS, Wright JJ, Bakhshi A.
    Oncogene Res; 1988 Feb 04; 2(3):263-75. PubMed ID: 3285301
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Oligonucleotides induce apoptosis restricted to the t(14;18) DHL-4 cell line.
    Morelli S, Alama A, Quattrone A, Gong L, Copreni E, Canti G, Nicolin A.
    Anticancer Drug Des; 1996 Jan 04; 11(1):1-14. PubMed ID: 8639245
    [Abstract] [Full Text] [Related]

  • 8. Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines.
    Reed JC, Kitada S, Takayama S, Miyashita T.
    Ann Oncol; 1994 Jan 04; 5 Suppl 1():61-5. PubMed ID: 8172820
    [Abstract] [Full Text] [Related]

  • 9. The role of Bcl-2 protein and autocrine growth factors in a human follicular lymphoma-derived B cell line.
    Blagosklonny MV, Neckers LM.
    Eur Cytokine Netw; 1995 Jan 04; 6(1):21-7. PubMed ID: 7795171
    [Abstract] [Full Text] [Related]

  • 10. Preservation of functional and regulatory domains of expressed bcl-2 genes in non-Hodgkin's lymphoma.
    Dirks W, Nolte M, Werner M, Jäger K, Koch C, Drexler HG.
    Leukemia; 1996 Jan 04; 10(1):150-8. PubMed ID: 8558921
    [Abstract] [Full Text] [Related]

  • 11. Cellular pharmacology of P-ethoxy antisense oligonucleotides targeted to Bcl-2 in a follicular lymphoma cell line.
    Gutiérrez-Puente Y, Tari AM, Ford RJ, Tamez-Guerra R, Mercado-Hernandez R, Santoyo-Stephano M, Lopez-Berestein G.
    Leuk Lymphoma; 2003 Nov 04; 44(11):1979-85. PubMed ID: 14738153
    [Abstract] [Full Text] [Related]

  • 12. Topographical dissociation of BCL-2 messenger RNA and protein expression in human lymphoid tissues.
    Chleq-Deschamps CM, LeBrun DP, Huie P, Besnier DP, Warnke RA, Sibley RK, Cleary ML.
    Blood; 1993 Jan 15; 81(2):293-8. PubMed ID: 8422456
    [Abstract] [Full Text] [Related]

  • 13. Analysis of BCL2 and MYC expression in non-Hodgkin's lymphomas by in situ hybridization: correlation with chromosome translocations.
    Murty VV, Ladanyi M, Houldsworth J, Mikraki V, Chaganti RS.
    Diagn Mol Pathol; 1992 Dec 15; 1(4):221-8. PubMed ID: 1342969
    [Abstract] [Full Text] [Related]

  • 14. Pseudonegative BCL2 protein expression in a t(14;18) translocation positive lymphoma cell line: a need for an alternative BCL2 antibody.
    Masir N, Campbell LJ, Jones M, Mason DY.
    Pathology; 2010 Apr 15; 42(3):212-6. PubMed ID: 20350212
    [Abstract] [Full Text] [Related]

  • 15. Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression.
    Kitada S, Takayama S, De Riel K, Tanaka S, Reed JC.
    Antisense Res Dev; 1994 Apr 15; 4(2):71-9. PubMed ID: 7950302
    [Abstract] [Full Text] [Related]

  • 16. Overexpression of the Bcl-2 protein increases the half-life of p21Bax.
    Miyashita T, Kitada S, Krajewski S, Horne WA, Delia D, Reed JC.
    J Biol Chem; 1995 Nov 03; 270(44):26049-52. PubMed ID: 7592801
    [Abstract] [Full Text] [Related]

  • 17. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence.
    Ziegler A, Luedke GH, Fabbro D, Altmann KH, Stahel RA, Zangemeister-Wittke U.
    J Natl Cancer Inst; 1997 Jul 16; 89(14):1027-36. PubMed ID: 9230884
    [Abstract] [Full Text] [Related]

  • 18. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins.
    Gautschi O, Tschopp S, Olie RA, Leech SH, Simões-Wüst AP, Ziegler A, Baumann B, Odermatt B, Hall J, Stahel RA, Zangemeister-Wittke U.
    J Natl Cancer Inst; 2001 Mar 21; 93(6):463-71. PubMed ID: 11259472
    [Abstract] [Full Text] [Related]

  • 19. Protamine-fragment peptides fused to an SV40 nuclear localization signal deliver oligonucleotides that produce antisense effects in prostate and bladder carcinoma cells.
    Benimetskaya L, Guzzo-Pernell N, Liu ST, Lai JC, Miller P, Stein CA.
    Bioconjug Chem; 2002 Mar 21; 13(2):177-87. PubMed ID: 11906253
    [Abstract] [Full Text] [Related]

  • 20. Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides.
    Reed JC, Stein C, Subasinghe C, Haldar S, Croce CM, Yum S, Cohen J.
    Cancer Res; 1990 Oct 15; 50(20):6565-70. PubMed ID: 2208117
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.